Quality of care indicators for gout management.
暂无分享,去创建一个
W. Bilker | J. Farrar | J. Allison | K. Saag | T. Mikuls | C. MacLean | Jason J. Olivieri | Fausto G Patino
[1] G. Peterson,et al. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy , 2004, European Journal of Clinical Pharmacology.
[2] G. Fonarow. Quality Indicators for the Management of Heart Failure in Vulnerable Elders , 2001, Annals of Internal Medicine.
[3] C. MacLean. Quality Indicators for the Management of Osteoarthritis in Vulnerable Elders , 2001, Annals of Internal Medicine.
[4] J. Schnelle,et al. Quality Indicators for the Management of Urinary Incontinence in Vulnerable Community-Dwelling Elders , 2001, Annals of Internal Medicine.
[5] Paul Shekelle,et al. Assessing Care of Vulnerable Elders: Methods for Developing Quality Indicators , 2001, Annals of Internal Medicine.
[6] B. Bates-Jensen. Quality Indicators for Prevention and Management of Pressure Ulcers in Vulnerable Elders , 2001, Annals of Internal Medicine.
[7] C. MacLean,et al. Quality Indicators for the Management of Osteoporosis in Vulnerable Elders , 2001, Annals of Internal Medicine.
[8] T. Chow,et al. Quality Indicators for Dementia in Vulnerable Community-Dwelling and Hospitalized Elders , 2001, Annals of Internal Medicine.
[9] C. Benesch,et al. Development of Performance Measures for Acute Ischemic Stroke , 2001, Stroke.
[10] P. Friedmann,et al. Appropriateness of medication selection for older persons in an urban academic emergency department. , 1999, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[11] W. Braun,et al. The incidence and management of osteoporosis, gout, and avascular necrosis in recipients of renal allografts functioning more than 20 years (level 5A) treated with prednisone and azathioprine. , 1999, Transplantation proceedings.
[12] J P Kahan,et al. The reproducibility of a method to identify the overuse and underuse of medical procedures. , 1998, The New England journal of medicine.
[13] L. E. Peterson,et al. Eliciting expert opinion using the Delphi technique: identifying performance indicators for cardiovascular disease. , 1998, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[14] P. Shekelle,et al. Assessing the Predictive Validity of the RAND/UCLA Appropriateness Method Criteria for Performing Carotid Endarterectomy , 1998, International Journal of Technology Assessment in Health Care.
[15] D. Gifford,et al. Development of a quality of care measurement system for children and adolescents. Methodological considerations and comparisons with a system for adult women. , 1997, Archives of pediatrics & adolescent medicine.
[16] E. Thervet,et al. Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout. , 1997, Transplantation.
[17] M A Hlatky,et al. Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization. , 1996, The New England journal of medicine.
[18] K. Wegscheider,et al. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol. , 1996, The Journal of rheumatology.
[19] Sanders Km,et al. A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. , 1996 .
[20] P. Pillans,et al. A survey of allopurinol dosage prescribing. , 1995, The New Zealand medical journal.
[21] R. Kravitz,et al. Validity of criteria used for detecting underuse of coronary revascularization. , 1995, JAMA.
[22] D. Hunter,et al. Qualitative Research: Consensus methods for medical and health services research , 1995 .
[23] C M Ashton,et al. A Method of Developing and Weighting Explicit Process of Care Criteria for Quality Assessment , 1994, Medical care.
[24] L. Leape,et al. Coronary angiography and revascularization: defining procedural indications through formal group processes. The Canadian Revascularization Panel, the Canadian Coronary Angiography Panel. , 1994, The Canadian journal of cardiology.
[25] J. Devlin,et al. Observations and effects of educational consults on allopurinol prescribing. , 1992, The Canadian journal of hospital pharmacy.
[26] G. Mccarthy,et al. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. , 2010, Arthritis and rheumatism.
[27] H. Cheung,et al. The mitogenic response to stimulation with basic calcium phosphate crystals is accompanied by induction and secretion of collagenase in human fibroblasts. , 1991, Arthritis and rheumatism.
[28] R. Kuncl,et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. , 1991, The Journal of rheumatology.
[29] V. Sharman,et al. Azathioprine and allopurinol: a potentially dangerous combination , 1990, Journal of internal medicine.
[30] Bullock Pw,et al. Intermittent control of hyperuricemia in the treatment of gout. , 1989 .
[31] R. Day,et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. , 1988, British journal of clinical pharmacology.
[32] S. Ralston,et al. Alcohol and response to treatment of gout , 1988, British medical journal.
[33] Wallace Sl,et al. Review: systemic toxicity associated with the intravenous administration of colchicine--guidelines for use. , 1988 .
[34] J. Levin,et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. , 1988, The Journal of rheumatology.
[35] R. Fraser,et al. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. , 1987, The Journal of the Royal College of General Practitioners.
[36] P. Brooks,et al. Does colchicine work? The results of the first controlled study in acute gout. , 1987, Australian and New Zealand journal of medicine.
[37] S. Wallace,et al. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. , 1986, Arthritis and rheumatism.
[38] J. Scott,et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. , 1985, British journal of clinical pharmacology.
[39] P. Fritsch,et al. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. , 1985, British medical journal.
[40] A. Wade,et al. Clinical Experience with Isoxicam in Patients with Acute Gout , 1985, The British journal of clinical practice.
[41] U. Deesomchok,et al. Piroxicam in treatment of acute gout high dose versus low dose. , 1985, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[42] Karachalios Gn. Treatment of acute gouty arthritis with piroxicam. , 1985 .
[43] K. Hande,et al. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. , 1984, The American journal of medicine.
[44] R. Eberl,et al. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. , 1983, Arzneimittel-Forschung.
[45] H. Simmonds,et al. Allopurinol treatment and its effect on renal function in gout: a controlled study. , 1982, Annals of the rheumatic diseases.
[46] G. Mcinnes,et al. Acute adverse reactions attributed to allopurinol in hospitalised patients. , 1981, Annals of the rheumatic diseases.
[47] J. Zazgornik,et al. Increased danger of bone marrow damage in simultaneous azathioprine-allopurinol therapy. , 1981, International journal of clinical pharmacology, therapy, and toxicology.
[48] J. Scott,et al. Acute gout during hypouricaemic therapy: prophylaxis with colchicine. , 1980, Annals of the rheumatic diseases.
[49] G. Sacchetti,et al. Intravenous Indoprofen for Prompt Relief of Acute Gout: A Regimen-Finding Study , 1980, The Journal of international medical research.
[50] J. Klinenberg,et al. Benzbromarone as a long-term uricosuric agent. , 1980, Advances in experimental medicine and biology.
[51] H. Simmonds,et al. A controlled study of the effect of long term allopurinol treatment on renal function in gout. , 1980, Advances in experimental medicine and biology.
[52] J. Scott,et al. Double-blind trial of feprazone and phenylbutazone in acute gout. , 1980, Current medical research and opinion.
[53] F. Matzkies,et al. The action of benzbromarone in relation to age, sex and accompanying diseases. , 1980, Advances in experimental medicine and biology.
[54] G. Elion,et al. Studies with allopurinol in patients with impaired renal function. , 1980, Advances in experimental medicine and biology.
[55] J. E. Murphy. Piroxicam in the Treatment of Acute Gout: A Multicentre Open Study in General Practice , 1979, The Journal of international medical research.
[56] G. Lupton,et al. The allopurinol hypersensitivity syndrome. , 1979, Journal of the American Academy of Dermatology.
[57] W. Fessel. Renal outcomes of gout and hyperuricemia. , 1979, The American journal of medicine.
[58] H. Rubinstein,et al. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. , 1979, Arthritis and rheumatism.
[59] D. Nashel,et al. Ibuprofen in the treatment of acute gouty arthritis. , 1978, JAMA.
[60] A. Ruotsi,et al. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial. , 1978, Scandinavian journal of rheumatology. Supplement.
[61] O. Khoo,et al. Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. , 1977, Australian and New Zealand journal of medicine.
[62] T. Reynolds,et al. Allopurinol-hypersensitivity vasculitis and liver damage. , 1977, The Western journal of medicine.
[63] J. Scott,et al. Multi-centre trial of naproxen and phenylbutazone in acute gout. , 1977, Advances in experimental medicine and biology.
[64] Yu Tf. Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone. , 1976 .
[65] Y. Lertratanakul,et al. Effect of fenoprofen calcium on acute gouty arthritis. , 1976, Arthritis and rheumatism.
[66] D. Levinson,et al. Clinical evaluation of benzbromarone: a new uricosuric drug. , 1976, Arthritis and rheumatism.
[67] C. Smyth,et al. The influence of allopurinol on renal function in gout. , 1975, Arthritis and rheumatism.
[68] J. Scott,et al. Single daily dose of allopurinol. , 1975, Annals of the rheumatic diseases.
[69] S. Tolchin,et al. Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. , 1975, JAMA.
[70] J. Young,et al. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. , 1974, Archives of internal medicine.
[71] Robert G. Godfrey,et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. , 1974, Arthritis and rheumatism.
[72] J. Scott,et al. Withdrawal of allopurinol in patients with gout. , 1974, Advances in experimental medicine and biology.
[73] F. Delbarre,et al. Treatment of gout and hyperuricaemia by benzbromarone, ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran. , 1974, Advances in experimental medicine and biology.
[74] J. Rosenfeld,et al. Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects. , 1974, Advances in experimental medicine and biology.
[75] J. Case,et al. The Treatment of Acute Gout with Naproxen , 1975, Scandinavian journal of rheumatology. Supplement.
[76] C. Smyth,et al. Comparison of indomethacin and phenylbutazone in acute gout. , 1973, Annals of the rheumatic diseases.
[77] P. Cuq. Experience Francaise Du Traitement De La Crise De Goutte Aigue Par Le Naproxen - C 1674 , 1973 .
[78] J. Scott,et al. Effect of weight-loss on plasma and urinary levels of uric acid. , 1972, Lancet.
[79] R. Mills. Severe hypersensitivity reactions associated with allopurinol. , 1971, JAMA.
[80] R. Grahame,et al. Clinical survey of 354 patients with gout. , 1970, Annals of the rheumatic diseases.
[81] M. Thompson,et al. A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. , 1970, Annals of physical medicine.
[82] J. Davis. Safety and effectiveness of colchicine by intravenous administration in the treatment of gout. , 1969, The Journal of clinical pharmacology and the journal of new drugs.
[83] G. Hitchings,et al. Renal clearance of oxipurinol, the chief metabolite of allopurinol. , 1968, The American journal of medicine.
[84] C. Reed,et al. Lead in dringking water. , 1967, Lancet.
[85] B. Emmerson. Regimen of indomethacin therapy in acute gouty arthritis. , 1967, British medical journal.
[86] H. Simmonds,et al. Allopurinol in the treatment of uraemic patients with gout. , 1967, Annals of the rheumatic diseases.
[87] B. Amor,et al. Treatment of Gout with Allopurinol , 1966, Annals of the rheumatic diseases.
[88] J. Scott,et al. Session II: Primary Hyperuricaemia and Gout , 1966 .
[89] R. P. Glover,et al. Treatment of Gout with Allopurinol and Sulphinpyrazone in Combination and with Allopurinol Alone* , 1966, Annals of the rheumatic diseases.
[90] J. Houpt. The effect of allopurinol (HPP) in the treatment of gout. , 1965, Arthritis and rheumatism.
[91] C. Smyth. Studies with allopurinol (HPP) in patients with tophaceous gout. , 1965, Arthritis and rheumatism.
[92] T. Yü,et al. The effect of allopurinol in primary and secondary gout. , 1965, Arthritis and rheumatism.
[93] J. Seegmiller,et al. THE EFFECTIVENESS OF THE XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN THE TREATMENT OF GOUT. , 1965, Annals of internal medicine.
[94] P. Boardman,et al. 208.--INDOMETHACIN IN THE TREATMENT OF ACUTE GOUT. , 1965, The Practitioner.
[95] A. Gutman,et al. EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT. , 1964, The American journal of medicine.
[96] J. Scott,et al. 4-Hydroxypyrazolo (3,4-d) Pyrimidine (HPP) in the Treatment of Gout , 1964, Annals of the rheumatic diseases.
[97] Rw Rundres. Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout , 1963 .
[98] R. Persellin,et al. The use of sulfinpyrazone in the treatment of gout. , 1961, JAMA.
[99] L. Carmichael. Treatment of acute gout with injection of colchicine. , 1959, Journal of the American Medical Association.
[100] A. Gutman,et al. Protracted uricosuric therapy in tophaceous gout. , 1957, Lancet.
[101] J. Davis,et al. The effect of intravenous colchicine on acute gout. , 1954, The American journal of medicine.
[102] R. Schaffarzick,et al. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. , 1952, Journal of the American Medical Association.
[103] J. Talbott,et al. The clinical and metabolic effects of benemid in patients with gout. , 1951, Transactions of the Association of American Physicians.